BIOMAT Database Logo BIOMAT Database Logo

Type-specific antibody responses of volunteers immunized with 23-valent pneumococcal polysaccharide vaccine. 1985

M A Mufson, and D Hughey, and E Lydick

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D001428 Bacterial Vaccines Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease. Bacterial Vaccine,Bacterin,Vaccine, Bacterial,Vaccines, Bacterial
D013296 Streptococcus pneumoniae A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals. Diplococcus pneumoniae,Pneumococcus
D022242 Pneumococcal Vaccines Vaccines or candidate vaccines used to prevent infections with STREPTOCOCCUS PNEUMONIAE. Pneumococcal Polysaccharide Vaccine,Pneumococcal Vaccine,Pneumovax,Pnu-Imune Vaccine,Pnu Imune Vaccine,PnuImune Vaccine,Polysaccharide Vaccine, Pneumococcal,Vaccine, Pneumococcal,Vaccine, Pneumococcal Polysaccharide,Vaccines, Pneumococcal

Related Publications

M A Mufson, and D Hughey, and E Lydick
Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine.
September 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
M A Mufson, and D Hughey, and E Lydick
23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia.
July 2017, The Lancet. Infectious diseases,
M A Mufson, and D Hughey, and E Lydick
23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia.
August 2017, The Lancet. Infectious diseases,
M A Mufson, and D Hughey, and E Lydick
23-valent pneumococcal polysaccharide vaccine. WHO position paper.
October 2008, Releve epidemiologique hebdomadaire,
M A Mufson, and D Hughey, and E Lydick
Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.
August 2016, Human vaccines & immunotherapeutics,
M A Mufson, and D Hughey, and E Lydick
Sex differences in antibody responses to the 23-valent pneumococcal polysaccharide vaccination.
October 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
M A Mufson, and D Hughey, and E Lydick
[Effectiveness of 23-valent pneumococcal polysaccharide vaccine on adult pneumococcal disease].
September 2020, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine],
M A Mufson, and D Hughey, and E Lydick
Serum antibody responses to vaccination with 23-valent pneumococcal vaccine in splenectomized patients.
November 1994, Zentralblatt fur Bakteriologie : international journal of medical microbiology,
M A Mufson, and D Hughey, and E Lydick
Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine.
June 2008, Vaccine,
M A Mufson, and D Hughey, and E Lydick
Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
May 2007, Vaccine,
Copied contents to your clipboard!